The purpose of this investigation was to identify newer antimicrobial agents that may be useful in the therapy of melioidosis. The in vitro susceptibilities of 199 clinical isolates of Pseudomonas pseudomallei to 22 antibiotics were determined by standard disk diffusion, and those to 13 antibiotics were determined by agar dilution. Over 90% of the isolates were susceptible to imipenem, piperacillin-tazobactam, piperacillin, ceftazidime, ticarcillinclavulanate, ampicillin-sulbactam, and carumonam by both methods. Standard disk diffusion yielded unacceptably high false-susceptibility results with aztreonam, ciprofloxacin, and temafloxacin. Piperacillin, ceftazidime, imipenem, and ciprofloxacin were not bactericidal for three selected P. pseudomallei strains as determined by time-kill curve methods. Furthermore, addition of ciprofloxacin to piperacillin, ceftazidime, or imipenem did not enhance bactericidal activity. One hundred ninety-four strains showed weak P-lactamase production that did not increase upon incubation with cefoxitin. These findings suggest that several newer antimicrobial agents may prove useful in the treatment of melioidosis. However, results of susceptibility studies involving P. pseudomallei and newer agents must be interpreted with caution.
Melioidosis, an infection caused by Pseudomonas pseudomallei, is endemic in Thailand, other parts of Southeast Asia, and northern Australia (3, 19, 21, 28) . The diagnosis of melioidosis is being made with increasing frequency in Thailand, where over 700 cases were reported at the National Workshop on Melioidosis in 1986 (28) . Septicemic melioidosis was seen in 57.4% of 686 patients evaluated, and 44.9% had pulmonary involvement. The overall mortality rate among infected patients exceeded 40% (28) . Treatment with conventional antibiotics, such as chloramphenicol, tetracycline, kanamycin, or trimethoprim-sulfamethoxazole, is usually ineffective in patients with disseminated septicemic infections, whose mortality rates approach 90% (21, 28) . New antimicrobial agents with enhanced activity against P. pseudomallei are needed to reduce the morbidity and mortality associated with melioidosis. To identify new, potentially more effective therapy, we determined the susceptibilities of 199 clinical isolates of P. pseudomallei to several new antimicrobial agents by using disk diffusion and agar dilution. P-Lactamase activity was measured by hydrolysis of nitrocephin before and after cefoxitin induction. Selected antibiotics were tested for bactericidal activity and synergy against representative strains by using the time-kill method.
(Part of this research was presented at the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles, Calif., 23 to 20 h at 37°C, cell numbers were determined by plating for the viable count. The culture was diluted with normal saline to give an initial inoculum of 105 to 106 CFU/ml. Tests were done in 100-ml bottles containing 10-ml samples of the above-described broth cultures with the required concentrations of antibiotics. Piperacillin, ceftazidime, and imipenem were tested either alone or in combination with ciprofloxacin at breakpoint concentrations (64, 8, 4, and 1 ,ug/ml). The cultures were incubated at 37°C on a shaker at 150 rpm. Samples (100 ,ul) were removed at 0, 4, and 24 h, and surviving bacteria were determined by plating 10-fold serial saline dilutions in duplicate on Mueller-Hinton agar. Bactericidal effect was determined as .2-order-of-magnitude killing at 24 h. Similar experiments were also performed with strains 2 and 3 at the MIC and at one-half of the MBC of the above-described antibiotics.
P-Lactamase assay. P-Lactamase activity was determined by a chromogenic microtiter assay with a nitrocefin substrate. Nitrocefin was eluted with 10 ml of 0.1 M phosphate buffer (pH 7.0) from 50 commercially prepared disks (Cefinase disks; BBL Microbiology Systems, Cockeysville, Md.). Overnight Mueller-Hinton broth cultures of P. pseudomallei were diluted 1:20 in Mueller-Hinton broth, and 150 pl was added to each of two wells on a microtiter plate. After 2 to 3 h at 37°C, cefoxitin (10 p,g/ml in 0.1 M phosphate buffer) was added to one well to induce P-lactamase production. An equal volume of phosphate buffer was added to uninduced wells. After 2 h at 37°C, 25 ,ul of nitrocefin was added to each well. After overnight incubation at room temperature, wells were examined for pinkness indicating nitrocefin hydrolysis. A mutant of P. aeruginosa that produces high levels of chromosomal ,-lactamase constitutively (provided by Christine C. Sanders, Creighton University) was used as the positive control.
RESULTS
Disk diffusion tests with 22 antibiotics were performed on 199 isolates of P. pseudomallei. These included 189 shiny, 6 mucoid, and 4 wrinkled yellow-to-white colony morphotypes of the organism. As shown in Table 1 , less than 20% of the strains were susceptible to trimethoprim-sulfamethoxazole and kanamycin, two drugs that are often part of (Table 1) . However, for aztreonam, ciprofloxacin, and temafloxacin, the false-susceptibility rates by standard disk diffusion were 5, 49, and 52%, respectively (Table 2) . Similarly, regression line analysis plots indicated poor correlation between disk diffusion and agar dilution cutoff points for these three drugs (Fig. 1) .
In time-kill curve studies, none of the antibiotics examined produced progressive killing over 24 h (Fig. 2) . At 4 h, each of the antibiotics examined had produced a weak bactericidal effect; however, this was not sustained over the 24 h of the test. Addition of ciprofloxacin to each of the P-lactam antibiotics did not enhance killing (Fig. 2) . Similar results were obtained by using antibiotic concentrations equal to the breakpoint, the MIC, and one-half of the MBC (data not shown). Drug carryover was unlikely undet our testing conditions, since decreasing numbers of surviving bacterial colonies were observed as the original culture samples were serially diluted.
One hundred ninety-four strains weakly produced P-lactamase. Of the five that did not produce ,B-lactamase, three were susceptible to ampicillin, ticarcillin, quinolones, and rifampin. Cefoxitin induction only minimally increased P-lactamase production. Virtually all isolates were resistant to ampicillin and ticarcillin but susceptible to ampicillinsulbactam and ticarcillin-clavulanate (Table 1) . Two P-lactamase-producing strains were highly resistant to P-lactam-,-lactamase inhibitors with a ticarcillin-clavulanate MIC of >256 ,ug/ml for one strain and an ampicillin-sulbactam MIC of 128 pug/ml for the other.
DISCUSSION
Recommendations for the use of tetracycline, chloramphenicol, kanamycin, and trimethoprim-sulfamethoxazole for treatment of melioidosis are based on previous in vitro studies (4, 12-14, 17, 18) . We confirmed the previously reported high prevalence of susceptibility among P. pseudomallei to tetracycline and chloramphenicol, but most of our isolates were resistant to kanamycin and trimetho- Time-kill curves of P. pseudomallei 1 (A, B, and C), 2 (D, E, and F), and 3 (G, H, and I) against piperacillin (pip), ciprofloxacin (cip), and piperacillin plus ciprofloxacin (pip/cip) (upper row); ceftazidime (ceftaz), ciprofloxacin, and ceftazidine plus ciprofloxacin (ceftaz/cip) (middle row); and imipenem (imip), ciprofloxacin, and imipenem plus ciprofloxacin (imip/cip) (lower row). may be explained in part by their bacteriostatic activities and the in vitro antagonism demonstrated by most combinations (9, 12) .
A number of recent in vitro studies have tested P. pseudomallei strains for susceptibility to newer antibiotics (2, 3, 6-8, 16, 20, 23, 28, 29, 31, 33, 34) . Potentially useful antibiotics with MICs for 90% of the strains tested well below therapeutic levels in serum included imipenem, piperacillin, ceftazidime, carumonam, azlocillin, mezlocillin, amoxicillin-clavulanate, and ticarcillin-clavulanate. Agents with MICs for 90% of the strains tested at or above peak therapeutic levels included cefoperazone, cefotaxime, and aztreonam. The MICs of moxalactam, quinolones (ciprofloxacin, ofloxacin, norfloxacin, pefloxacin, amifloxacin, and enoxacin), and ticarcillin for 90% of the strains tested uniformly exceeded therapeutic levels in blood. P. pseudomallei is intrinsically resistant to narrow-and expanded-spectrum cephalosporins and the aminoglycosides, with the exception of kanamycin (3, 12, 17) .
Our isolates had susceptibility patterns similar to those shown in prior studies. Imipenem was the most active drug tested, followed by piperacillin-tazobactam, piperacillin, ceftazidime, carumonam, ticarcillin-clavulanate, and ampicillin-sulbactam. These drugs inhibited 90% of strains at concentrations of 1-to 32-fold lower than the achievable therapeutic levels. Moderate-to-poor activities were observed with cefixime, cefpirome, aztreonam, ampicillin, ticarcillin, amdinocillin, and rifampin. P. pseudomallei is a facultative intracellular pathogen able to survive and multiply within phagocytes (10, 11, 27, 32) . The new broad-spectrum quinolone antibiotics penetrate phagocytes well (32) . In general, however, they have shown limited activity against P. pseudomallei in vitro (2, 6, 8, 20, 33, 34 (22) . The P-lactamase-producing strains in our study which were highly resistant to ticarcillin-clavulanate also had relatively high imipenem MICs (4 ,ug/ml). This suggests the possibility of other mechanisms of antibiotic resistance, such as decreased outer membrane permeability, a known mechanism of resistance to imipenem in P.
aeruginosa (30) .
In summary, by both standard disk diffusion and agar dilution MIC, the most active antibiotics against 199 P. pseudomallei strains were imipenem, piperacillin-tazobactam, piperacillin, ceftazidime, carumonam, ticarcillin-clavulanate, and ampicillin-sulbactam. Piperacillin, ceftazidime, and imipenem were not bactericidal for P. pseudomallei in vitro. However, these agents and the newer ,-lactam-plactamase inhibitor combinations warrant further study for treatment of melioidosis. The therapeutic value of ciprofloxacin in this setting is limited by the frequency of resistant strains of P. pseudomallei, the unacceptably high falsesusceptibility rates seen with disk diffusion testing, and the lack of in vitro synergy when tested in combination with piperacillin, ceftazidime, and imipenem. The findings of P-lactamase production in 97% of the strains, a 2-to >64-fold reduction in MICs when ,-lactamase inhibitors were added to 3-lactam antibiotics, and susceptibilities to 1-lactam antibiotics in ,-lactamase-negative strains suggest a role for ,-lactamase in the resistance of P. pseudomallei to ,-lactam antibiotics. Resistance to 13-lactam-P-lactamase inhibitor combinations, as well as decreased susceptibility of P. pseudomallei to new oral quinolones and some expandedspectrum P-lactams, indicates that there are additional resistance mechanisms.
